Cite
HARVARD Citation
Herbst, R. et al. (2023). Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of clinical oncology. 41 (10), pp. 1830-1840. [Online].